Hostname: page-component-848d4c4894-nr4z6 Total loading time: 0 Render date: 2024-05-06T18:54:49.728Z Has data issue: false hasContentIssue false
  • English
  • Français

Quality of Life in Parkinson's Disease Patients Following Adjunctive Tolcapone Therapy: Results of an Open-Label, Multicenter, Community-Based Trial

Published online by Cambridge University Press:  07 November 2014

Kapil Sethi ,
Stewart Factor  and
Ray Watts
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective: To examine changes in quality of life (QOL) and global clinical status after 30 days of adjunctive treatment with tolcapone, a reversible inhibitor of catechol-O-methyltransferase, in patients with fluctuating Parkinson's disease.

Methods: This 30-day, multicenter, open-label, community-based study enrolled fluctuating Parkinson's disease patients to receive tolcapone 100 mg TID as an adjunct to levodopa/carbidopa. The primary end point was QOL change assessed using the Parkinson's Disease Questionnaire (PDQ)-8. Clinical change was assessed using the investigator-rated Clinical Global Impression of Improvement Scale (CGI-I).

Results: Fifty-six physicians enrolled 202 patients; 138 (68%) were ≥65 years of age and 116 (57%) had Parkinson's disease for ≥5 years. The mean PDQ-8 total score improved from 42.1 to 34.8 after 30 days of tolcapone (P<.0001). Sixty-nine percent of patients improved on the CGI-I. Physicians planned to continue tolcapone beyond the 30 days in 72%, most commonly because of positive changes in motor function and overall general improvement. No patient discontinued because of liver adverse events.

Conclusions: Adjunctive tolcapone treatment was associated with statistically significant improvement in QOL in fluctuating Parkinson's disease patients. A majority of patients experienced clinical benefits and continued treatment beyond the end of this study. No liver-related adverse events were reported.

Type
Original Research
Information
CNS Spectrums , Volume 15 , Issue 1 , January 2010 , pp. 27 - 32
Copyright
Copyright © Cambridge University Press 2010

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1.Gallagher, DA, Schrag, A.Impact of newer pharmacological treatments on quality of life in patients with Parkinson's disease. CNS Drugs. 2008; 22: 563–586.Google Scholar
2.Koller, W, Lees, A, Doder, M, Hely, M.Randomized trial of tolcapone versus pergolide as add-on to levodopa therapy in Parkinson's disease patients with motor fluctuations. Mov Disord. 2001; 16: 858–866.CrossRefGoogle ScholarPubMed
3.Welsh, MD, Dorflinger, E, Chernik, D, Waters, C.Illness impact and adjustment to Parkinson's disease: before and after treatment with tolcapone. Mov Disord. 2000; 15: 497–502.Google Scholar
4.Ahlskog, JE, Muenter, MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord. 2001; 16: 448–458.CrossRefGoogle ScholarPubMed
5.Welsh, M, McDermott, MP, Holloway, RG, Plumb, S, Pfeiffer, R, Hubble, J.Development and testing of the Parkinson's disease quality of life scale. Mov Disord. 2003; 18: 637–645.CrossRefGoogle ScholarPubMed
6.de Boer, AG, Wijker, W, Speelman, JD, de Haes, JC. Quality of life in patients with Parkinson's disease: development of a questionnaire. J Neurol Neurosurg Psychiatry. 1996; 61: 70–74.Google Scholar
7.Calne, S, Schulzer, M, Mak, E, et al. Validating a quality of life rating scale for idiopathic parkinsonism: Parkinson's Impact Scale (PIMS). Parkinsonism Relat Disord. 1996; 2: 55–61.CrossRefGoogle ScholarPubMed
8.Peto, V, Jenkinson, C, Fitzpatrick, R, Greenhall, R.The development and validation of a short measure of functioning and well being for individuals with Parkinson's disease. Qual Life Res. 1995; 4: 241–248.Google Scholar
9.Peto, V, Jenkinson, C, Fitzpatrick, R.PDQ-39: a review of the development, validation and application of a Parkinson's disease quality of life questionnaire and its associated measures. J Neurol. 1998; 245 (Suppl 1): S10–S14.Google Scholar
10.Jenkinson, C, Fitzpatrick, R, Peto, V, Greenhall, R, Hyman, N.The PDQ-8: development and validation of a short-form Parkinson's disease questionnaire. Psychol Health. 1997; 12: 805–814.Google Scholar
11.Leegwater-Kim, J, Waters, C.Tolcapone in the management of Parkinson's disease. Expert Opin Pharmacother. 2006; 7: 2263–2270.CrossRefGoogle ScholarPubMed
12.Tasmar® (tolcapone) prescribing information. Physicians' Desk Reference, 60th ed. Montvale, NJ: Thompson PDR; 2006.Google Scholar
13.Kaakkola, S, Gordin, A, Mannisto, PT. General properties and clinical possibilities of new selective inhibitors of catechol O-methyltransferase. Gen Pharmacol. 1994; 25: 813–824.Google Scholar
14.Dingemanse, J, Jorga, K, Zurcher, G, et al. Pharmacokinetic-pharmacodynamic interaction between the COMT inhibitor tolcapone and single-dose levodopa. Br J Clin Pharmacol. 1995; 40: 253–262.CrossRefGoogle ScholarPubMed
15.Dingemanse, J, Jorga, K, Zurcher, G, et al. Multiple-dose clinical pharmacology of the catechol-O-methyl-transferase inhibitor tolcapone in elderly subjects. Eur J Clin Pharmacol. 1996; 50: 47–55.Google Scholar
16.Kurth, MC, Adler, CH, Hilaire, MS, et al. Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: a multicenter, double-blind, randomized, placebo-controlled trial. Neurology. 1997; 48: 81–87.Google Scholar
17.Baas, H, Beiske, AG, Ghika, J, et al. Catechol-O-methyltransferase inhibition with tolcapone reduces the “wearing off” phenomenon and levodopa requirements in fluctuating parkinsonian patients. J Neurol Neurosurg Psychiatry. 1997; 63: 421–428.Google Scholar
18.Rajput, AH, Martin, W, Saint-Hilaire, MH, Dorflinger, E, Pedder, S.Tolcapone improves motor function in parkinsonian patients with the “wearing-off” phenomenon: a double-blind, placebo-controlled, multicenter trial. Neurology. 1997; 49: 1066–1071.Google Scholar
19.Dupont, E, Burgunder, JM, Findley, LJ, Olsson, JE, Dorflinger, E.Tolcapone added to levodopa in stable parkinsonian patients: a double-blind placebo-controlled study. Tolcapone in Parkinson's Disease Study Group II (TIPS II). Mov Disord. 1997; 12: 928–934.Google Scholar
20.Waters, CH, Kurth, M, Bailey, P, et al. Tolcapone in stable Parkinson's disease: efficacy and safety of long-term treatment. Neurology. 1997; 49: 665–671.CrossRefGoogle ScholarPubMed
21.Watts, R, Kricorian, G. Evaluation of liver-related adverse events with tolcapone: a review of 7-years of worldwide safety data [abstract P400]. Presented at: 2005 World Congress of Neurology, November 5-11, 2005, Sydney, Australia. Mov Disord 2005; 20 Suppl 10: S118.Google Scholar
22. Tasmar® (tolcapone) tablets [package insert]. Aliso Viejo CA, USA: Valeant Pharmaceuticals International; 2006.Google Scholar
23.Katsarou, Z, Bostantjopoulou, S, Peto, V, Kafantari, A, Apostolidou, E, Peitsidou, E.Assessing quality of life in Parkinson's disease: can a short-form questionnaire be useful? Mov Disord. 2004; 19: 308–312.CrossRefGoogle ScholarPubMed
24.Adler, CH, Singer, C, O'Brien, C, et al. Randomized, placebo-controlled study of tolcapone in patients with fluctuating Parkinson disease treated with levodopacarbidopa. Arch Neurol. 1998; 55: 1089–1095.CrossRefGoogle ScholarPubMed
25.Bergner, M, Bobbitt, RA, Carter, WB, Gilson, BS. The Sickness Impact Profile: development and final revision of a health status measure. Med Care. 1981; 19: 787–805.CrossRefGoogle ScholarPubMed